Brian Park, PharmD

Drug Information Specialist https://www.pulmonologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Lung Infection

Statin Use Linked to Reduced Death Risk in Hospitalized COVID-19 Patients

Brian Park, PharmD

September 15, 2021

Study authors analyzed data from 10,541 hospitalized patients with active COVID-19 disease to evaluate the relationship between the use of statins and COVID-19 outcomes.

Pneumonia

Pneumococcal 15-Valent Conjugate Vaccine Immunogenic, Safe in Healthy Infants

Brian Park, PharmD

August 31, 2021

The multicenter, randomized, double-blind, active-comparator-controlled phase 3 PNEU-PED study included 1720 healthy infants enrolled at 42-90 days of age.

Pulmonary Hypertension

Inhaled Imatinib Designated Orphan Drug for Pulmonary Arterial Hypertension

Brian Park, PharmD

August 31, 2021

AER-901 is an investigational drug-device combination therapy that consists of a nebulized formulation of imatinib and the Fox device, a breath-actuated smart nebulizer.

General Pulmonology

Pfizer, BioNTech Submit Supplemental BLA for COVID-19 Vaccine Booster

Brian Park, PharmD

August 30, 2021

The application includes data from a phase 3 trial that evaluated a booster dose of Comirnaty in 306 adult participants 18 to 55 years of age who were previously vaccinated with a 2-dose primary regimen.

General Pulmonology

Biologics License Application for Moderna COVID-19 Vaccine Submitted to FDA

Brian Park, PharmD

August 27, 2021

The application includes data from the phase 3 COVE study that evaluated the Moderna COVID-19 vaccine in 30,420 adults 18 years of age and older.

Lung Infection

Long-Acting Monoclonal Antibodies Look Promising for COVID-19 Prevention

Brian Park, PharmD

August 26, 2021

The randomized, double-blind, placebo-controlled, multicenter PROVENT trial included 5197 participants aged 18 years and older who would benefit from AZD7442.

Smoking

Pfizer Expands Chantix Recall Due to Nitrosamine Impurity

Brian Park, PharmD

August 25, 2021

To date, the Company has not received any reports of adverse events related to this recall.

Lung Infection

Phase 1 Data Support Booster Dose of Pfizer-BioNTech COVID-19 Vaccine

Brian Park, PharmD

August 23, 2021

The phase 1 study is part of clinical trial program evaluating the safety, tolerability and immunogenicity of a booster dose of the Pfizer-BioNTech COVID-19 vaccine.

General Pulmonology

Case Series Describes COVID-19 Vaccine-Associated Myocarditis in Children

Brian Park, PharmD

August 13, 2021

The Centers for Disease Control and Prevention continues to recommend COVID-19 vaccination for all individuals 12 years of age and older.

Xiuning Le, MD, PhD, discusses the future of tepotinib in the treatment of NSCLC. Dr Le is an author of a phase 2 study on tepotinib, a highly selective MET inhibitor.

Lung Cancer

Atezolizumab Gets Priority Review as Adjuvant Treatment for Early NSCLC

Brian Park, PharmD

August 9, 2021

The sBLA is supported by data from the IMpower010 study that compared atezolizumab with best supportive care in 1005 adults with Stage IB-IIIA NSCLC after resection and adjuvant chemotherapy.

Next post in Lung Cancer